We have located links that may give you full text access.
Journal Article
Research Support, Non-U.S. Gov't
Review
Improving the outcomes in children with bacterial meningitis.
Current Opinion in Infectious Diseases 2009 June
PURPOSE OF REVIEW: Intravenous dexamethasone (DXM) is used as adjuvant medication in bacterial meningitis of childhood, although no single study has proven its efficacy against death, severe neurological sequelae, or hearing impairment. Meta-analyses do not facilitate interpretation, because they combine profoundly dissimilar populations and neglect the child's presenting condition. Important new information was revealed by a large double-blind, prospective study from Latin America in which the effects of oral glycerol (GLY) were compared with those of DXM.
RECENT FINDINGS: Of 654 children, mainly with Haemophilus influenzae type b or pneumococcal meningitis, 166 received DXM, 159 DXM and GLY, 166 GLY, and 163 placebo. Neither of the adjuvants prevented hearing impairment, regardless of agent or timing of antibiotic. Instead of the causative agent, the presenting status was the only characteristic that associated with all three outcomes. GLY, but not DXM, prevented neurological sequelae, especially in Haemophilus influenzae type b meningitis. The likely mechanism of GLY is the increase in plasma osmolality. Cerebrospinal fluid genome counts differ enormously and predict death in pneumococcal but not Haemophilus influenzae type b meningitis.
SUMMARY: Being the first adjuvant in childhood meningitis with documented clinically meaningful benefits, GLY seriously challenges the position of DXM as adjuvant medication. Severe neurological sequelae are relieved by GLY, whereas no current medication prevents hearing impairment.
RECENT FINDINGS: Of 654 children, mainly with Haemophilus influenzae type b or pneumococcal meningitis, 166 received DXM, 159 DXM and GLY, 166 GLY, and 163 placebo. Neither of the adjuvants prevented hearing impairment, regardless of agent or timing of antibiotic. Instead of the causative agent, the presenting status was the only characteristic that associated with all three outcomes. GLY, but not DXM, prevented neurological sequelae, especially in Haemophilus influenzae type b meningitis. The likely mechanism of GLY is the increase in plasma osmolality. Cerebrospinal fluid genome counts differ enormously and predict death in pneumococcal but not Haemophilus influenzae type b meningitis.
SUMMARY: Being the first adjuvant in childhood meningitis with documented clinically meaningful benefits, GLY seriously challenges the position of DXM as adjuvant medication. Severe neurological sequelae are relieved by GLY, whereas no current medication prevents hearing impairment.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app